Tricuspid Regurgitation in the ElderlY - Trial NCT05784883
Access comprehensive clinical trial information for NCT05784883 through Pure Global AI's free database. This phase not specified trial is sponsored by Al-Azhar University and is currently Recruiting. The study focuses on Tricuspid Regurgitation. Target enrollment is 700 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Al-Azhar University
Timeline & Enrollment
N/A
Aug 01, 2022
Aug 01, 2029
Primary Outcome
Prevalence of tricuspid valve regurgitation in the elderly,All-cause mortality,Cardiovascular mortality,Rehospitalization for congestive heart failure
Summary
Tricuspid regurgitation (TR) is the second most common VHD after MR. Its prevalence also
 increases with age, with an estimated incidence of up to 6% in elderly population. When
 adjusted to age (among other confounders), survival is worse for patients with moderate and
 severe TR. We aim to explore the prevalence, mechanisms, and clinical implications of
 tricuspid valve regurgitation in elderly subjects screened at a tertiary center in Cairo,
 Egypt.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05784883
Non-Device Trial